DE69823660D1 - Methode zur identifizierung von tumorantigenen mit autoantikörpern in serum - Google Patents

Methode zur identifizierung von tumorantigenen mit autoantikörpern in serum

Info

Publication number
DE69823660D1
DE69823660D1 DE69823660T DE69823660T DE69823660D1 DE 69823660 D1 DE69823660 D1 DE 69823660D1 DE 69823660 T DE69823660 T DE 69823660T DE 69823660 T DE69823660 T DE 69823660T DE 69823660 D1 DE69823660 D1 DE 69823660D1
Authority
DE
Germany
Prior art keywords
protein antigens
sera
patients
identification
identified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69823660T
Other languages
English (en)
Inventor
M Hanash
David Misek
Robert Hinderer
Latha Prasanan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21967731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69823660(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Michigan filed Critical University of Michigan
Application granted granted Critical
Publication of DE69823660D1 publication Critical patent/DE69823660D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69823660T 1997-06-26 1998-06-26 Methode zur identifizierung von tumorantigenen mit autoantikörpern in serum Expired - Lifetime DE69823660D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5083297P 1997-06-26 1997-06-26
PCT/US1998/013295 WO1999000671A2 (en) 1997-06-26 1998-06-26 Method for identification of tumor antigens with autoantibodies in serum

Publications (1)

Publication Number Publication Date
DE69823660D1 true DE69823660D1 (de) 2004-06-09

Family

ID=21967731

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69823660T Expired - Lifetime DE69823660D1 (de) 1997-06-26 1998-06-26 Methode zur identifizierung von tumorantigenen mit autoantikörpern in serum

Country Status (9)

Country Link
EP (1) EP0991945B2 (de)
JP (2) JP4065574B2 (de)
AT (1) ATE266203T1 (de)
AU (1) AU8267398A (de)
CA (2) CA2294514C (de)
DE (1) DE69823660D1 (de)
DK (1) DK0991945T4 (de)
ES (1) ES2216295T5 (de)
WO (1) WO1999000671A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1295668A (zh) * 1998-02-13 2001-05-16 牛津糖科学(英国)有限公司 用于肝细胞癌诊断的方法和组合物
US6645465B2 (en) 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
US6306615B1 (en) * 1999-08-19 2001-10-23 Tularik Inc. Detection method for monitoring β tubulin isotype specific modification
US7214498B2 (en) 2001-03-23 2007-05-08 Benaroya Research Institute At Virginia Mason Tumor associated antigens and methods of using the same
DE10151051B4 (de) * 2001-09-14 2007-07-12 Zeidler, Reinhard, Dr. Identifizierung von Antigenen durch xenogene, allogene oder autologe Antikörper-vermittelte Präzipitation
US20050221305A1 (en) * 2001-11-09 2005-10-06 Benaroya Research Institute At Virginia Mason Antigen panels and methods of using the same
GB2424070B (en) * 2002-11-14 2007-06-27 Univ Nottingham Methods for preparing tumour marker proteins
AU2003903317A0 (en) * 2003-06-27 2003-07-10 Proteome Systems Intellectual Property Pty Ltd Method of isolating a protein
KR20080073740A (ko) * 2005-11-10 2008-08-11 유니버시티 오브 캔터키 폐암 진단 검사
EP2041569A4 (de) * 2006-07-08 2009-11-18 Univ Kentucky Res Found Assay zur diagnose von lungenkrebs
JP2011107064A (ja) * 2009-11-20 2011-06-02 Nitto Boseki Co Ltd クラスリン重鎖に対する自己抗体の免疫測定方法、それに用いるキット、及びそれを用いた癌判定方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2062675A1 (en) * 1991-04-09 1992-10-10 Sandra S. Fenton Endometrial antigen, composition, test kit and method for endometrial antibody determination
US5405749A (en) * 1991-12-06 1995-04-11 Polans; Arthur S. Method for identifying and purifying a cancer associated retinopathy autoantigen, and testing patient serum for the autoantibody to the autoantigen
AU6960694A (en) * 1993-05-28 1994-12-20 Medical University Of South Carolina Endometrial proteins, antigenic compositions and methods for detecting endometriosis

Also Published As

Publication number Publication date
WO1999000671A2 (en) 1999-01-07
JP2007333744A (ja) 2007-12-27
CA2665707A1 (en) 1999-01-07
CA2294514C (en) 2009-09-01
EP0991945B1 (de) 2004-05-06
AU8267398A (en) 1999-01-19
EP0991945B2 (de) 2008-02-20
ES2216295T3 (es) 2004-10-16
DK0991945T4 (da) 2008-06-09
CA2665707C (en) 2013-02-12
CA2294514A1 (en) 1999-01-07
ATE266203T1 (de) 2004-05-15
WO1999000671A3 (en) 1999-06-10
EP0991945A2 (de) 2000-04-12
JP4065574B2 (ja) 2008-03-26
JP2002508835A (ja) 2002-03-19
DK0991945T3 (da) 2004-07-26
ES2216295T5 (es) 2008-06-01

Similar Documents

Publication Publication Date Title
RU2408735C2 (ru) Способ предсказания ответа на лечение
BR0208603A (pt) Marcadores de tumor para carcinoma de células renais
CY1112631T1 (el) ΜΕΘΟΔΟΙ ΤΑΥΤΟΠΟΙΗΣΗΣ ΟΓΚΩΝ ΠΟΥ ΑΠΟΚΡΙΝΟΝΤΑΙ ΣΕ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ΕrbB2
DE69929185D1 (de) Tumormarker
Canelle et al. An efficient proteomics-based approach for the screening of autoantibodies
DE69839123D1 (de) Prostattumor polynukleotid- und antigenzusammensetzungen
DE69033842D1 (de) Äusserliche domäne von c-erbb-2:gp75
DE69839492D1 (de) Monoklonale antikörper zur apoptosis-induzierung
CY1108450T1 (el) Μεθοδος για την ανιχνευση ν-τελικου προβνρ
DE69823660D1 (de) Methode zur identifizierung von tumorantigenen mit autoantikörpern in serum
IL142971A0 (en) S100 proteins and autoantibodies as serum markers for cancer
GR3018371T3 (en) Method for identifying or determining proteins and applications therefor.
ES2141249T3 (es) Procedimiento para la identificacion de celulas humanas y animales que presentan la capacidad para una proliferacion ilimitada o para una formacion de tumores.
DE69126038T2 (de) Diagnose von krebs-metastasen durch das mts-1 gen
BR0010479A (pt) Gene tipo prp
NO901461L (no) Antistoffer mot retinoblastom-genprodukt og anvendelse derav.
WO2008099419A3 (en) Autoantibodies for protein antigens as markers for cancer of gingivo-buccal complex
DE69132144D1 (de) Menschliche phospholipase aktivierender proteinteil
CA2264963A1 (en) Protein markers for esophageal cancer
CN101762708A (zh) 用于诊断非小细胞肺癌的血清标志物
WO2001065262A3 (en) Reagents and methods useful for detecting diseases of the breast
Kirkeby et al. Staining of electrophoretically separated enamel proteins
DE69716728T2 (de) Zytofluorometrisches verfahren zur bestimmung von antikörper gegen tumorantigene im serum
Grups et al. Serum Antibodies Against Cell Membrane Extracts of Human Bladder Carcinomas

Legal Events

Date Code Title Description
8332 No legal effect for de